A Phase 1/2 clinical trial testing AXO-Lenti-PD (OXB102), Axovant‘s experimental gene therapy for Parkinson’s disease, has completed dosing of all four adults in a second group in its dose-escalation part of the study. Six-month data on these patients is expected by year’s end. AXO-Lenti-PD is a one-time gene therapy…
Vanderbilt University announced the opening of the Warren Center for Neuroscience Drug Discovery, promoting research into treatments for neurological disorders such as Parkinson’s disease, Alzheimer’s, and schizophrenia. The center, which will specialize in translating basic research into viable treatments, was made possible by a $20 million donation from…
Comparing the genomes of people with Parkinson’s disease to the specific genes expressed by cell types in the nervous system revealed an unexpected association between Parkinson’s and the digestive nervous system, according to a study. Another surprising result linked Parkinson’s to cells called oligodendrocytes, nervous system cells that…
Aspen Neuroscience has raised $70 million to advance the development of  Parkinson’s disease therapies using patients’ own cells. The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression.
An interdisciplinary team of researchers has developed a substance that may improve the differential diagnosis of Parkinson’s disease based on brain imaging — potentially allowing physicians to distinguish between patients who are sensitive to the side effects of parkinsonian medications and those who are not. Levodopa is one…
Get regular updates to your inbox.